Literature DB >> 3572804

Effect of methamphetamine on neurotensin concentrations in rat brain regions.

A A Letter, K Merchant, J W Gibb, G R Hanson.   

Abstract

High doses of methamphetamine (METH) induced 200 to 300% increases in the neurotensin-like immunoreactivity (NTLI) concentrations of the substantia nigra and striatum in rats after a single or multiple drug doses; smaller but significant increases of 30 to 50% were observed in the hypothalamus and hippocampus after multiple, but not single, METH administrations whereas no measurable changes were detected in the NTLI levels of the periaqueductal gray area or the amygdala. These METH-induced increases in NTLI concentrations were attenuated by coadministration of haloperidol in the substantia nigra, hypothalamus and hippocampus, indicating a possible involvement of dopamine receptors in these tissues. In the striatum haloperidol alone produced significant increases in NTLI levels; these increases were additive with those induced by METH treatment demonstrating that the neurotensin pathways associated with the striatum are regulated differently from that of the other brain areas examined. The implications of these findings to the relationship between dopamine and neurotensin transmitter systems are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572804

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Brain levels of neuropeptides in human chronic methamphetamine users.

Authors:  Paul S Frankel; Mario E Alburges; Lloyd Bush; Glen R Hanson; Stephen J Kish
Journal:  Neuropharmacology       Date:  2007-06-28       Impact factor: 5.250

3.  The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

Authors:  Ricardo Cáceda; Elisabeth B Binder; Becky Kinkead; Charles B Nemeroff
Journal:  Schizophr Res       Date:  2011-11-21       Impact factor: 4.939

4.  Mephedrone alters basal ganglia and limbic neurotensin systems.

Authors:  Christopher L German; Amanda H Hoonakker; Annette E Fleckenstein; Glen R Hanson
Journal:  J Neurochem       Date:  2014-04-19       Impact factor: 5.372

5.  Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Synapse       Date:  2015-06-11       Impact factor: 2.562

6.  Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia.

Authors:  Paul S Frankel; Amanda J Hoonakker; Mario E Alburges; Jacob W McDougall; Lisa M McFadden; Annette E Fleckenstein; Glen R Hanson
Journal:  J Pharmacol Exp Ther       Date:  2010-12-02       Impact factor: 4.030

7.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

8.  Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics.

Authors:  K M Merchant; D M Dorsa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat.

Authors:  Glen R Hanson; Amanda J Hoonakker; Christina M Robson; Lisa M McFadden; Paul S Frankel; Mario E Alburges
Journal:  J Pharmacol Exp Ther       Date:  2013-05-17       Impact factor: 4.030

10.  Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system.

Authors:  Mario E Alburges; Amanda J Hoonakker; Glen R Hanson
Journal:  Eur J Pharmacol       Date:  2007-07-24       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.